XT
ESPR

XTX Topco’s Esperion Therapeutics ESPR Stock Holding History

XTX Topco’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.46M Buy
462,386
+248,155
+116% +$694K 0.02% 1434
2026
Q1 		$587K Buy
214,231
+52,257
+32% +$165K 0.01% 1888
2025
Q4 		$599K Buy
+161,974
New +$523K 0.02% 1444
2025
Q1 		– Sell
-24,494
Closed -$53.9K – 2588
2024
Q4 		$53.9K Sell
24,494
-131,806
-84% -$308K ﹤0.01% 1884
2024
Q3 		$258K Sell
156,300
-208,381
-57% -$421K 0.02% 1288
2024
Q2 		$810K Buy
364,681
+321,859
+752% +$757K 0.07% 441
2024
Q1 		$115K Buy
+42,822
New +$104K 0.02% 1337
2023
Q4 		– Sell
-519,129
Closed -$509K – 1733
2023
Q3 		$509K Buy
519,129
+102,377
+25% +$148K 0.09% 391
2023
Q2 		$579K Buy
416,752
+106,971
+35% +$149K 0.1% 285
2023
Q1 		$493K Buy
+309,781
New +$1.6M 0.1% 301
2022
Q2 		– Sell
-18,686
Closed -$87K – 922
2022
Q1 		$87K Buy
+18,686
New +$80.2K 0.04% 534

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

XTX Topco's ESPR Position: Q2 2026 in Review

XTX Topco increased its Esperion Therapeutics (ESPR) stake by 116% in Q2 2026, buying an estimated $694K and bringing the position to 462,386 shares worth $1.46M. The position accounts for 0.02% of the portfolio, ranked #1434.

XTX Topco first reported a position in ESPR in Q1 2022 and has held it in 11 quarters since. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • XTX Topco held 462,386 shares of Esperion Therapeutics worth $1.46M as of Q2 2026.
  • XTX Topco bought 248,155 Esperion Therapeutics shares in Q2 2026, an estimated $694K.
  • Esperion Therapeutics made up 0.02% of XTX Topco's portfolio in Q2 2026, its #1434 holding.
  • XTX Topco first reported a position in Esperion Therapeutics in Q1 2022 and has held it in 11 quarters since.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.